Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Gelfand JM1, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS. Clinical studies are ongoing to evaluate the efficacy of new therapeutic agents for variety of indications. Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation. Risk Profile in Psoriasis Patients by the Use of Pro-inflammatory Markers in Skin and Cardiovascular Disease. Director, Psoriasis and Phototherapy Treatment Center, Department of Dermatology, University of Pennsylvania. Inflammation in Patients with Moderate to Severe Psoriasis as measured by 18F -Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT): A Pilot Study. AS: Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice Setting.
Background: There is a lack of comparative effectiveness research, particularly in the clinical setting, guiding psoriasis therapy. Conclusions: In the clinical setting, the biologic and combination therapies are superior to the traditional systemic therapies in the treatment of psoriasis. Gelfand, Joel M Research Area: (05) Comparative Effectiveness Research, 05-AR-101 Comparative Effectiveness (CE) of Biologics in Autoimmune Rheumatic and Skin Diseases Title of application: Comparativ. Effectiveness of Biologics for Psoriasis Psoriasis is a chronic, inflammatory Th-1, Th-17 mediated disease that affects over 7 million Americans. Thus, to make informative treatment decisions and improve the quality of care of moderate to severe psoriasis patients, it is urgent that comparative effectiveness studies be conducted in this area. (2012) Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. CER include randomized controlled trials and systematic reviews.
The chronic inflammatory skin disease that typically follows a relapsing and remitting course, resulting from the abnormal activation of T cells and associated increase in cytokines in affected tissues, can transpire at any age (Gould and Dyer, 2011). Key Words: psoriasis, biologics, access, formulary, efficacy, safety. Psoriasis is an often-debilitating, chronic condition characterized by systemic inflammation that causes thick, red, and scaly skin lesions. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. FDA-approved treatments for moderate to severe psoriasis, which affects approximately 33 of psoriasis patients,2 have burgeoned since 2003, when only acitretin, cyclosporine, methotrexate, and phototherapy were available. As of June 2008, FDA-approved treatments for moderate to severe psoriasis included 3 oral systemic medications, 5 systemic biologic medications, and phototherapy.
The Comparative Efficacy Of Traditional Systemic, Biologic, And Combination Therapies In The Treatment Of Psoriasis: An Expansion Study
However, the comparative effectiveness of topical and laser treatment of psoriasis is unknown because these treatments have not been directly compared in a prospective clinical study. The variety of systems and advised parameters hampers a systematic evaluation. The inflammatory skin diseases treated with PDL consisted of: psoriasis, acne vulgaris, lupus erythematodes, granuloma faciale, sarcoidosis, eczematous lesions, papulopustular rosacea, lichen sclerosis, granuloma annulare, Jessner lymphocytic infiltration of the skin, and reticular erythematous mucinosis. Psoriasis is a chronic, immune-mediated, inflammatory skin condition that impacts quality of life through physical, psychological, and social distress and is associated with systemic consequences including arthritis and cardiovascular disease. Despite advances in psoriasis care, effective long-term treatment of psoriasis remains a challenge to both patients and physicians. Topical treatment, phototherapy, and non-biologic systemic treatments have various limitations to consider when constructing treatment plans (Table 1). Comparative data post-marketing is not yet available for this biologic. Psoriasis is a common, chronic, relapsing, inflammatory skin disorder with a strong genetic basis. Third-line therapy which refers to systemic biological therapies that use molecules designed to block specific molecular steps important in the development of psoriasis, such as the TNF antagonists adalimumab, etanercept and infliximab, and ustekinumab, anti-IL12-23 monoclonal antibody. A Cochrane review found that potent to very potent corticosteroids perform as well as vitamin D analogues, with a lower incidence of local adverse events but combining corticosteroid with vitamin D analogue was the most effective. Helliwell P, et al; Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. Does systemic anti-inflammatory therapy reduce the risk? Given the chronic nature of immune-mediated inflammatory diseases, clinicians must be vigilant in monitoring the safety of these agents in the long-term environment. Current comparative efficacy studies of systemic treatments for psoriasis are primarily small-scale, short-term studies, which provide only a small snapshot on the nature of the drug in question.